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Depressive Symptoms as Predictors of
Mortality in Patients With COPD*
Jacob N. de Voogd, MS; Johan B. Wempe, PhD; Gerard H. Koe¨ter, PhD;
Klaas Postema, PhD; Eric van Sonderen, PhD; Adelita V. Ranchor, PhD;
James C. Coyne, PhD; and Robbert Sanderman, PhD
Objective: Prognostic studies of mortality in patients with COPD have mostly focused on
physiologic variables, with little attention to depressive symptoms. This stands in sharp contrast
to the attention that depressive symptoms have been given in the outcomes of patients with other
chronic health conditions. The present study investigated the independent association of
depressive symptoms in stable patients with COPD with all-cause mortality.
Methods: The baseline characteristics of 121 COPD patients (78 men and 43 women; mean  SD
age, 61.5 9.1 years; and mean FEV1, 36.9 15.5% predicted) were collected on hospital admission
to a pulmonary rehabilitation center. The data included demographic variables, body mass index
(BMI), post-bronchodilator therapy FEV1, and Wpeak (peak workload Wpeak). Depressive symp-
toms were assessed using the Beck depression inventory. The vital status was ascertained using
municipal registrations. In 8.5 years of follow-up, 76 deaths occurred (mortality rate, 63%). Survival
time ranged from 88 days to 8.5 years (median survival time, 5.3 years). The Cox proportional hazard
model was used to quantify the association of the baseline characteristics (ie, age, sex, marital status,
smoking behavior, FEV1, BMI, Wpeak, and depressive symptoms) with mortality.
Results:Depressive symptoms (odds ratio OR, 1.93; 95% confidence interval CI, 1.12 to 3.33) were
associated with mortality in patients with COPD, independent of other factors including male sex
(OR, 1.73; 95% CI, 1.03 to 2.92), older age (OR, 1.05; 95% CI, 1.02 to 1.08), and lower Wpeak (OR,
0.98; 95% CI, 0.97 to 0.99).
Conclusions: This study provides evidence that depressive symptoms assessed in stable patients with
COPD are associated with their subsequent all-cause mortality. (CHEST 2009; 135:619–625)
Key words: COPD; depression; psychology; pulmonary rehabilitation; smoking
Abbreviations: BDI Beck depression inventory; BMI body mass index; CI confidence interval; OR odds ratio;
Wpeak peak workload
I n the last few decades, there has been a globalincrease in mortality from COPD, which is ex-
pected to be the third most frequent cause of death
by the year 2020.1 Studies predicting mortality in
patients with COPD have mainly focused on physi-
ologic variables, and only occasionally on psycholog-
ical variables. Airflow limitation (FEV1),2,3 hypercap-
nia,4 hypoxemia,5 increased dyspnea,6 and poor
nutritional status7,8 have all been found to be risk
factors for mortality in COPD patients. Also, vari-
ables such as reduced Wpeak,9,10 poor health-related
quality of life,11 and living without a partner12 were
found to be associated with increased mortality. Celli
and coworkers13 proposed a multidimensional grad-
ing system, consisting of graded scores of body mass
index (BMI), airflow obstruction, dyspnea and
Wpeak (or BODE index), and they have found that
it is a useful tool for predicting the risk of death in
COPD patients.
Depressive symptoms are prevalent among COPD
patients, but have not been given much consider-
ation as prognostic factors, despite their having
been associated with higher mortality in other
diseases,14–17 as well as with all-cause mortality. For
example, Frasure-Smith and coworkers18 demon-
strated that both subclinical depressive symptoms
and major depression are related to mortality in
patients after myocardial infarction.
Estimates of the prevalence of depression and
depressive symptoms tend to be high among COPD
Original Research
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patients, varying from 6 to  60%.19–21 This large
variance in estimates can be attributed to differences
in sampling, but particularly to variability in the
instruments and cutoff scores used to measure de-
pression, as well as a conflation of elevations in
self-reported depressive symptoms with the less
prevalent and less commonly studied psychiatric
diagnosis of depression.20
Some studies have demonstrated only a weak
association between psychological disturbance22 or
health-related quality of life11 and mortality in
COPD patients. Yet, depressive symptoms were
found to be strong predictors for mortality (odds
ratios ORs, 1.9,23 3.6,24 and 2.725), independent of
other disease severity and other risk factors, in
COPD patients in three studies. It is noteworthy that
two of the studies23,24 focused on COPD patients
who had been hospitalized for acute exacerbation.
The assessment of the depression symptoms was
conducted during or shortly after (within 2 to 4
weeks) hospitalization for an exacerbation, which
may have been reflected in increased the levels of
depressive symptomatology. Only one study25 dem-
onstrated that adjusted depressive symptoms were
associated with 3-year mortality and not with 1-year
mortality in stable COPD patients. In contrast, two
other studies26,27 did not find an association between
mortality and depression after adjustment for disease
severity. These conflicting data raise the question of
whether depression symptoms are also related to
mortality in a group of clinically stable patients with
COPD. This question became the basis for the
present study, which investigated the association of
depressive symptoms and all-cause mortality in sta-
ble patients with COPD, adjusting for known risk
factors such as age, marital status, smoking, BMI,
Wpeak and FEV1 percent predicted.
Materials and Methods
Subjects
Our study sample consisted of 121 consecutive stable patients,
all with COPD (FEV1 80% predicted) that had been diagnosed
according to the American Thoracic Society guidelines,28 who
were referred for pulmonary rehabilitation between September
1998 and March 2000. All patients had been clinically stable for
at least 6 weeks and did not require an increase in medication or
hospitalization. Exclusion criteria were the inability to perform
lung function tests and/or ergometry, refusal to fill out psycho-
logical questionnaires, and the presence of a comorbidity such as
malignancy or severe heart failure, that limits the prognosis.
Measurements
Patient Characteristics: On hospital admission, demographic
data, such as sex, age and marital status were recorded. Marital
status was dichotomized into the following two groups: living with
a partner and living without a partner. Patients without a partner
included those patients who had never married, or were sepa-
rated or widowed. Smoking behavior was assessed by a self-report
questionnaire and was placed in one of the following two
categories: (0) never had smoked cigarettes or had been an
ex-smoker for  1 year; and (1) current smoker or had been an
ex-smoker for  1 year.
Depression: The presence of depressive symptoms was as-
sessed with the original Beck depression inventory (BDI) I.29,30
The BDI-I is a 21-item self-administered rating inventory mea-
suring attitudes and symptoms of depression. It takes approxi-
mately 10 min to complete. Total score ranges from 0 to 63, with
a higher score indicating more pathology. The scale has high
internal consistency, and good discriminant and convergent
validity.30 In the present article, we studied the impact of
depressive symptoms on mortality, but not the impact of major
depressive disorder. In our analyses, we used the recommended
cutoff level for clinically significant depressive symptoms in
otherwise healthy individuals (ie, BDI score 1931) to define the
high/low depressive symptoms distinction.
Physiologic Parameters: The BMI is reported as the weight in
kilograms divided by the square of the body height in meters.
Airflow obstruction was established by the FEV1, post-bronchodila-
tor therapy, expressed in liters and as a percentage of the
predicted value, and was assessed (Masterlab 4.521 plethysmo-
graph; Jaeger; Wu¨rzburg, Germany) according to American
Thoracic Society standards.28 Arterial blood gas levels at rest,
Pao2, and Paco2, were assessed while the patient was breathing
room air. Exercise capacity (ie, peak workload Wpeak) was
defined as the highest workload reached and was maintained for
at least 30 s during symptom-limited incremental cycle ergometry
testing (Oxycon pro; Cardinal Health; Dublin, OH).32 A protocol
with a 5 or 10 W/min increment in load was applied depending
on the estimated Wpeak, starting with 1 min of unloaded
pedaling and aiming at a duration of 6 to 12 min.
Mortality: The vital status of these patients was ascertained on
April 1, 2007, using municipal registrations. The rationale for
relying on all-cause mortality was that clinical assessments of the
cause of death are difficult to obtain, often incorrect, and always
involve a subjective judgement.33
Statistical Analysis
All analyses were performed using a statistical software pack-
age (SPSS, version 12.0.1 for Windows; SPSS Inc; Chicago, IL).
All 121 patients were included in the main analyses. However,
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additional analyses focused on the subsample of 102 patients for
whom Pao2 and Paco2 data were available. Continuous variables
are presented as the mean  SD, except for follow-up time,
which is presented as the median. Dichotomized variables are
presented in percentages. The relations between the variables
were presented as Pearson correlations for continuous variables
and  correlations for dichotomous variables. Univariate hazards
(ORs) associated with each variable were examined. Multivariate
Cox proportional hazard analyses with a stepwise forward likeli-
hood ratio method including all variables were used to quantify
the relationship between baseline variables and mortality and
95% confidence intervals (CIs) were estimated with significance
set at p  0.05. High/low depressive symptoms were plotted in
survival curves using Kaplan-Meier estimates.
Results
The characteristics of the patients (78 men and 43
women) are presented in Table 1. The mean age was
61.5  9.1 years. Their post-bronchodilator therapy
FEV1 was 36.9  15.5% predicted. With regard to
depression, 19.8% of patients tested above the stan-
dard cutoff score of  19 and were classified as
having moderate-to-severe depressive symptoms.
Of the 121 patients who participated in the study,
76 (63%) had died at the end of the study. The
median survival time for all patients was 5.3 years.
The median survival time for the patients who died
was 3.0 years (survival range, 88 days to 7.8 years).
The median survival time for the 45 patients (37%)
who were alive at the end of the study was 7.8 years
(survival range, 7.1 to 8.5 years).
Table 2 shows the correlations among key predic-
tor variables. High depressive symptoms are not
correlated with any of these variables except for
continued smoking behavior (r  0.27).
Table 3 shows the results of the Cox proportional
hazard analyses. On a univariate level, male gender,
older age, a lower Wpeak, and high depressive
symptoms are significantly related to mortality in
COPD patients.
These variables were entered into the multivariate
analysis. We found that high depressive symptoms
are significantly associated with mortality, indepen-
dent of male gender, older age, and lower Wpeak.
High depressive symptoms nearly double the mor-
tality risk in COPD patients when compared to low
depressive symptoms (OR, 1.93; 95% CI, 1.12 to
3.33). In a subsample of 102 patients for which both
Pao2 and Paco2 data were available, we found that
neither variable was correlated with depressive
Table 1—Characteristics of the COPD Patients*
Variables All Patients (n 121)
Male sex, % 65
Age, yr 61.5  9.1
With Partner, % 70
Smoking, %
NS or ES  1 yr 52
CS or ES  1 yr 48
FEV1
L 1.09  0.54
% predicted 36.9  15.5
GOLD stages II/III/IV, % 18.2/41.3/40.5
BMI, kg/m2 25.5  6.0
Wpeak, W 58.7  33.6
Pao2,† kPa 9.3  1.7
Paco2,† kPa 5.3  0.8
Depression BDI score 12.6  8.2
High depressive symptoms (BDI
score  19), %
20
Mortality rate, % 63
Median follow-up time for all
patients, yr
5.3
Median follow-up time for
survivors, yr
7.8
Median follow-up time for patients
who died, yr
3.0
*Values are given as the mean SD, unless otherwise indicated.
NS  never-smoker; ES  ex-smoker; CS  current smoker;
GOLD  Global Initiative for Chronic Obstructive Lung Disease.
†n  102.
Table 2—Correlations Between Possible Predictors for Mortality in COPD Patients (n  121)*
Variables 1 2 3 4 5 6 7 8
1. Sex (0 female) 1
2. Age in yr 0.22† 1
3. Partner (0 no) 0.23† 0.01 1
4. Smoking‡ 0.08 0.03 0.21† 1
5. FEV1 (L) 0.24§ 0.23† 0.23§ 0.12 1
6. FEV1 (% predicted) 0.04 0.08 0.15 0.11 0.90§ 1
7. BMI 0.13 0.10 0.11 0.22† 0.29§ 0.34§ 1
8. Wpeak 0.03 0.35§ 0.24§ 0.14 0.53§ 0.40§ 0.34§ 1
9. Depressive symptoms (0 low) 0.06 0.06 0.18 0.27§ 0.04 0.01 0.10 0.17
*All correlations are Pearson correlations except for dichotomous variables, where  correlations were used. See Table 1 for abbreviations not used
in the text.
†p  0.05.
‡0  NS or ES for  1 year; 1 CS or ES for  1 year.
§p  0.01.
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symptoms. Only lower Pao2 was associated with
mortality in the univariate analysis (OR, 0.98; 95%
CI, 0.96 to 0.99), but not in the multivariate analysis.
Paco2 was not associated with mortality in either
univariate or multivariate analyses. In this smaller
sample, high depressive symptoms remained signif-
icantly associated with mortality. We did not find any
significant interaction effects. In Figure 1, survival
curves using the Kaplan-Meier estimates are plotted
for the two groups (ie, those patients with high
depressive symptoms and those with low depressive
symptoms).
Discussion
This study provides preliminary evidence that
depressive symptoms are an independent prognostic
factor for mortality among stable COPD patients,
even when adjustments are made for risk factors
such as age, sex, and Wpeak. The association of
depressive symptoms and mortality has been dem-
onstrated in COPD patients assessed during or
shortly after hospitalization for an exacerbation.
However, to our knowledge, this is one of the first
studies demonstrating that there is an association
even in stable COPD patients. We observed this
association among clinically stable COPD patients
who had been referred for pulmonary rehabilitation,
which perhaps limits generalization to all COPD
patients. However, we believe that our results are
even more compelling because our patient group
was, on average, 10 years younger than the patients
in the earlier studies.23,24 The younger age and the
large number of deaths observed in our sample make
it more than plausible that age and age-related
morbidities are not the only contributing factors.
Our study is in line with and strengthens the evi-
dence in the recently published paper by Fan and
coworkers,25 which demonstrated the adjusted risk
of 3-year mortality among stable COPD patients
with BDI scores  15. The results of our study are
also in line with those from studies conducted in
different patient groups. For instance, in elderly
hospitalized patients with several medical condi-
tions14 and in patients after myocardial infarc-
tion,17,18 a modest-to-strong association between de-
pression and mortality has been demonstrated.
It is noteworthy that in the assessment of depres-
sion in patients with cardiovascular disease, some
sources have argued34–37 that depressive symptoms
obtained with instruments like the BDI are inflated
among patients with medical disease because of the
confounding of vegetative symptoms. This has moti-
vated Beck et al38 to revise the original BDI and
create the BDI-II. However, few studies have actu-
ally examined this question with appropriate meth-
odologies for detecting differential item functioning.
Simon et al39 looked at somatic and nonsomatic
depressive symptoms among depressed managed
care patients with diabetes, ischemic heart disease,
and COPD compared to patients without chronic
disease. They found only very minor deviations in
symptom reporting and found that all four Diagnos-
tic and Statistical Manual of Mental Disorders IV
somatic symptoms improved with treatment of de-
pression regardless of whether or not patients had
comorbid medical illness. Instruments, such as de-
pression subscale of the hospital anxiety and depres-
sion scale, which are constructed to avoid the assess-
Table 3—Predictors for Mortality in COPD patients,




OR 95% CI OR 95% CI
Sex (0  female) 1.67 1.02–2.73* 1.73 1.03–2.92*
Age in years 1.07 1.05–1.11† 1.05 1.02–1.08†
Partner (0  no) 0.67 0.42–1.07
Smoking 1.38 0.88–2.17
FEV1% predicted 0.99 0.97–1.01
BMI 0.96 0.92–1.00
Wpeak 0.98 0.97–0.99† 0.98 0.97–0.99†
Depressive symptoms
(0  low)
1.78 1.06–3.00* 1.93 1.12–3.33*
*p  0.05.
†p  0.001.
Figure 1. Kaplan-Meier curves for COPD patients with separate
lines for high and low depressive symptoms (adjusted for the
covariates sex, age, and Wpeak).
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ment of somatic symptoms, have not been shown to
be superior to conventional instruments for assess-
ing depression, such as the BDI.40,41 As with the
hospital anxiety and depression scale, the BDI is
not a diagnostic case finder for major depressive
disorder. However, on an individual level, a high
score can be used as a suitable indication for
follow-up assessment.
Some possible explanations can be offered for the
finding that depressive symptoms have prognostic
value in COPD patients. First, some studies42–44
have demonstrated that depression can affect the
hypothalamic-pituitary-adrenal axis functioning,
which could make health status deteriorate. Second,
depressive symptoms can impair self-care, as indi-
cated by insufficient nutritional intake, continued
smoking, lower activity levels, poor medication com-
pliance, and initiation of an action plan for exacer-
bation in addition to less adequate health-care seek-
ing, which also could lead to an accelerated decline
in health. In our study, we did not have data on
hypothalamic-pituitary-adrenal axis functioning or
follow-up data on behavioral factors. We suggest that
such data be collected in future studies.
In our sample, depressive symptoms were inde-
pendent of other known risk factors, except that
depressive symptoms were correlated with contin-
ued smoking or recent smoking cessation. However,
smoking behavior is not related to mortality in this
sample, which frustrates a search for mechanism. We
attempted to control for the influence of a number of
risk factors known to predict mortality, but our list
could have been incomplete and our measurement
imperfect. It has been suggested45 that the wide
range of conditions for which depressive symptoms
have been shown to predict mortality suggests either
a very general susceptibility or that confounding is at
play. Moreover, similar to other health conditions in
which depressive symptoms have been shown to
predict mortality, it has yet to be demonstrated that
improvement in depressive symptoms will yield de-
creased mortality. It is common a call for interven-
tion to be made when depressive symptoms are
observed to have a predictive value for mortality.
But, the empirical basis for that call is not typically
provided.
Some limitations of this study should be noted.
First, the data on the nature and numbers of comor-
bid conditions were not consistently recorded and
therefore were not included in the study. Data on
comorbidities could have provided us with additional
clues on a possible explanatory mechanism of the
association between depressive symptoms and mor-
tality. Second, the cause of death was not deter-
mined, so we studied all-cause mortality and not just
respiratory causes of death. The cause of death is
sometimes hard to establish, in particular when
patients die at home; death certificate data on the
actual cause of death are not independently validated
and are known to be less trustworthy.33 Third, our
study includes potentially modifiable risk factors
such as smoking behavior, BMI, Wpeak, and depres-
sive symptoms that may change in the course of time.
Also, we have no data on the prescription of antide-
pressants. The use of antidepressants might have
influenced our assessment of depressive symptoms
by lowering symptoms. However, most depression in
medically ill patients goes unrecognized or is inade-
quately treated, and the effects on depressive symp-
toms are further limited by poor patient adherence
to treatment and poor physician follow-up. Nonethe-
less, future research should include assessment of
patients’ receipt of antidepressants and psychological
treatment. Alterations in behavior, interventions, or
hospitalizations may affect prognosis. However, we
do not have follow-up data on psychological or
physiologic variables in our sample, or on the effects
of treatment during or after rehabilitation. Although
it is known that pulmonary rehabilitation may im-
prove recognized predictors of mortality such as
Wpeak, dyspnea, and quality of life, there is no
evidence yet that pulmonary rehabilitation is bene-
ficial with regard to survival.46 Further observational
studies of the correlates of depressive symptoms and
their specific components such as hopelessness47 or
somatic complaints48 are needed before proposing
interventions. Finally, the assessment of depressive
symptoms in our study was limited to a single point
in time. This assessment allowed a preliminary dem-
onstration of the value of assessing such symptoms,
but leaves unexplored questions about their stability
or trajectory over time, and particularly how changes
in these symptoms are related to changes in morbid-
ity and mortality. Taken together with findings of
the few other studies demonstrating the predictive
value of depressive symptoms in COPD, our re-
sults give encouragement to more ambitious stud-
ies of the course of depressive symptoms in rela-
tion to mortality.
In conclusion, this study demonstrates the associ-
ation of high levels of depressive symptoms in COPD
patients with mortality after adjustment for known
risk factors such as sex, age, and Wpeak. What is
needed next is the explication of both the determi-
nants of depressive symptoms, and the pathway
between these symptoms and mortality.
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